Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTYP01 tablets for early symptomatic Alzheimer's disease
CTR20253688Phase 2Active
- Sponsor
- Suzhou Aozong Biotechnology
- Start
- Dec 2025
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of FAB122 in Alzheimer's disease (AD), sponsored by Suzhou Aozong Biotechnology. Started Dec 2025; status: active.
02
Drugs
FAB122
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on CTR20253688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253688.